MINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Kevin Hykes will join its Board of Directors effective December 21, 2022.
“We are excited to welcome an executive with the depth of expertise of Kevin Hykes to our Board of Directors,” said John Nehra, lead independent director of CVRx. “His commercial experience in accelerating the growth of novel interventional therapies and his executive acumen will prove an invaluable resource as we continue to build our business and increase access to Barostim™ for patients globally.”
“I am delighted that Kevin is joining our Board of Directors and know that he will provide exceptional guidance to our management team,” added Nadim Yared, President and CEO of CVRx. “Kevin’s proven track record in our field will bring tremendous value to CVRx as we accelerate commercial adoption of Barostim.”
Kevin Hykes is an accomplished medical device industry executive with 30 years’ experience commercializing novel therapies on a global basis. Augmedics is a leader in augmented reality surgical navigation and Kevin is its President and CEO. Kevin was previously the President and CEO of Bardy Diagnostics. Hillrom purchased it in August 2021. Kevin was previously President and CEO, Relievant Medsystems, an operating partner at Versant Ventures, Chairman, CEO, and CEO, of Metavention, Inc., Chief Commercial Officer, Visiogen (Abbott), and CEO, Cameron Health (Boston Scientific). Kevin was a sixteen-year veteran of Medtronic’s CRM, Neurostimulation, Cardiac Surgery and other businesses. Kevin is an Operating Partner at Revival Healthcare Capital, and an independent member of Metavention, Inc. Kevin has a MBA from Northwestern University, and a BBA Information Systems from University of Wisconsin.
“I am honored to join the CVRx Board of Directors,” said Mr. Hykes. “I look forward to working with this excellent management team and to helping CVRx continue its momentum establishing Barostim as an important therapy for patients suffering from cardiovascular disease.”
CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim, an implantable device, delivers electrical pulses through the carotid vein wall to the baroreceptors. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. This therapy restores balance to the autonomic nervous systems and reduces the symptoms of heart disease. Barostim has been FDA-approved for heart failure patients in America. It also has the CE Mark in Europe for heart failure and resistant hypertension. Learn more about Barostim. www.cvrx.com.
Contact an investor
Mike Vallie, Mark Klausner